Better Therapeutics (NASDAQ:BTTX – Get Free Report) is expected to post its resultson Thursday, November 12th. Analysts expect Better Therapeutics to post earnings of ($0.21) per share and revenue of $6.58 million for the quarter.
Better Therapeutics Price Performance
Better Therapeutics stock opened at $0.00 on Tuesday. The stock has a market cap of $4,058.00, a P/E ratio of -0.00 and a beta of 0.91. Better Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.00.
About Better Therapeutics
Better Therapeutics was a digital therapeutics company focused on developing prescription software designed to address chronic metabolic and cardiometabolic conditions. Its approach combined behavioral therapy, personalized digital coaching and clinical content delivered through software intended for use alongside standard medical care.
The company’s lead product, AspyreRx, formerly known as BT-001, was authorized by the U.S. Food and Drug Administration in 2023 as a prescription digital therapeutic for adults with type 2 diabetes.
Read More
- Five stocks we like better than Better Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
